Amatu, A., Sartore-Bianchi, A. & Siena, S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.
Small-scale studies across multiple tumour types have consistently been able to correlate changes in functional imaging parameters during radiotherapy with disease outcomes.
Bland TAE has previously been described as effective in the management of liver metastases from multiple tumour types, including metastatic sarcoma and gastrointestinal stromal tumour [13, 14].
Given the low direct and supportive care costs of these agents, and their activity against multiple tumour types this study identifies an affordable potential anti-cancer therapy in developing countries where fiscal and other restraints limit the availability of conventional chemotherapy.
Oncomine analysis demonstrated downregulation of expression in multiple tumour types.
Pazopanib has shown clinical activity against multiple tumour types and is generally well tolerated.
Previously published data support this idea in multiple tumour types (Modjtahedi et al, 2014).
For example, the MYOD1 CpG island is methylated in multiple tumour types.
Recent developments suggest the possibility of blood-based screening for multiple tumour types.
Using these reagents we were able to extensively analyse CD70 expression in multiple tumour types.
Antitumour activity was observed for each treatment regimen and across multiple tumour types.
